Loading
A phase 2 trial of Acalabrutinib in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT02213926 by Acerta Pharma BV, with 124 participants enrolled, started 2015-03-02 and due to reach its primary completion in 2020-12-04. Interventions recorded: ACP-196 (acalabrutinib). Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/